| ID | Sequence | Length | GC content |
|---|---|---|---|
| AGAGAUGCGGUCGCCAUGGUGACUGAGGACCAGUGAGGCGGGAUGGGGU… | 3437 nt | 0.5749 | |
| ACUGAGAGACCGGAAAGCCUGGCAUUCCAGAGGGAGGGAAACGCAGCGG… | 3127 nt | 0.5702 | |
| AGUGCUGGCUUUGGCAUGAUGGGCACCUGGAGGGCCGCACUCCCGUUCC… | 2975 nt | 0.5684 | |
| AGAGCUCCCUGGUGACAGUCUGUGGCUGAGCAUGGCCCUCCCAGCCCUG… | 3064 nt | 0.5689 | |
| AGAGAUGCGGUCGCCAUGGUGACUGAGGACCAGUGAGGCGGGAUGGGGU… | 3044 nt | 0.5670 | |
| AGAGAUGCGGUCGCCAUGGUGACUGAGGACCAGUGAGGCGGGAUGGGGU… | 3061 nt | 0.5668 | |
| AGAGAUGCGGUCGCCAUGGUGACUGAGGACCAGUGAGGCGGGAUGGGGU… | 3463 nt | 0.5744 | |
| AGUGCUGGCUUUGGCAUGAUGGGCACCUGGAGGGCCGCACUCCCGUUCC… | 3242 nt | 0.5716 |
This gene encodes a member of the semaphorin family of soluble and transmembrane proteins. Semaphorins are involved in numerous functions, including axon guidance, morphogenesis, carcinogenesis, and immunomodulation. The encoded protein is a single-pass type I membrane protein containing an immunoglobulin-like C2-type domain, a PSI domain and a sema domain. It inhibits axonal extension by providing local signals to specify territories inaccessible for growing axons. It is an activator of T-cell-mediated immunity and suppresses vascular endothelial growth factor (VEGF)-mediated endothelial cell migration and proliferation in vitro and angiogenesis in vivo. Mutations in this gene are associated with retinal degenerative diseases including retinitis pigmentosa type 35 (RP35) and cone-rod dystrophy type 10 (CORD10). Multiple alternatively spliced transcript variants encoding different isoforms have been identified.[provided by RefSeq, Sep 2010]
A study in human myocardial biopsies from patients with dilated cardiomyopathy demonstrated that SEMA4A mRNA is upregulated in ischemic cardiomyopathy compared to volume overload cardiomyopathy and forms a negatively correlated pair with miR-218-5p, with their direct interaction validated by luciferase reporter assays [Bonet et al. DOI:10.3390/biom14050524]. In human sepsis patients, bioinformatics and validation analyses identified SEMA4A as a ligand for the PLXNB2 receptor within the SEMA4 signaling pathway, which is active in monocytes and associated with clinical outcomes [Liu et al. DOI:10.1590/1414-431X2025e14930].